The Experts below are selected from a list of 114 Experts worldwide ranked by ideXlab platform
Giulinana Gialdroni-grassi - One of the best experts on this subject based on the ideXlab platform.
-
Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
Infection, 1994Co-Authors: F. Bariffi, V. Clini, F. Ginesu, Patrizia Mangiarotti, Giulinana Gialdroni-grassi, Libera RomoliAbstract:Efficacy and tolerability of Flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18–87 years) were treates with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that Flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections. Die Wirksamkeit und Verträglichkeit von Flurithromycin Ethylsuccinat wurde bei Patienten mit Infektionen der tiefen Atemwege geprüft. 110 Patienten (38 Frauen, 72 Männer, im Alter von 18–87 Jahren) erhielten zweimal täglich eine Tablette Flurithromycin Ethylsuccinat zu 375 mg. Insgesamt wurden 62,9% der Patienten klinisch geheilt, 19% gebessert. Die Rate an befriedigendem klinischen Ansprechen lag somit bei 81,9%. Bei den meisten Patienten ging die Sputumproduktion zurück. Bei 47% hatte die Sputumproduktion nach Behandlungsende aufgehört (nur bei einem Patienten bestand zu Therapiebeginn keine Sputumproduktion). Purulentes oder mukopurulentes Sputum bestand vor Behandlung bei 80% und nach Behandlng bei 20% der Patienten. Bei 72 Patienten war eine bakteriologische Befundung möglich. In 80,2% der Fälle wurde der Erreger eliminiert. Bei acht der 110 behandelten Patienten traten Nebenwirkungen auf, die meist den Gastrointestinaltrakt betrafen. In einem Fall mußte die Behandlung abgebrochen werden. Diese Ergebnisse zeigen, daß Flurithromycin Ethylsuccinat ein wirksames und sicheres Medikament für die Behandlung tiefer Atemwegsinfektionen ist.
-
Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
Infection, 1994Co-Authors: F. Bariffi, V. Clini, F. Ginesu, Patrizia Mangiarotti, Libera Romoli, Giulinana Gialdroni-grassiAbstract:Efficacy and tolerability of Flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18-87 years) were treated with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that Flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections.
Libera Romoli - One of the best experts on this subject based on the ideXlab platform.
-
Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
Infection, 1994Co-Authors: F. Bariffi, V. Clini, F. Ginesu, Patrizia Mangiarotti, Giulinana Gialdroni-grassi, Libera RomoliAbstract:Efficacy and tolerability of Flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18–87 years) were treates with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that Flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections. Die Wirksamkeit und Verträglichkeit von Flurithromycin Ethylsuccinat wurde bei Patienten mit Infektionen der tiefen Atemwege geprüft. 110 Patienten (38 Frauen, 72 Männer, im Alter von 18–87 Jahren) erhielten zweimal täglich eine Tablette Flurithromycin Ethylsuccinat zu 375 mg. Insgesamt wurden 62,9% der Patienten klinisch geheilt, 19% gebessert. Die Rate an befriedigendem klinischen Ansprechen lag somit bei 81,9%. Bei den meisten Patienten ging die Sputumproduktion zurück. Bei 47% hatte die Sputumproduktion nach Behandlungsende aufgehört (nur bei einem Patienten bestand zu Therapiebeginn keine Sputumproduktion). Purulentes oder mukopurulentes Sputum bestand vor Behandlung bei 80% und nach Behandlng bei 20% der Patienten. Bei 72 Patienten war eine bakteriologische Befundung möglich. In 80,2% der Fälle wurde der Erreger eliminiert. Bei acht der 110 behandelten Patienten traten Nebenwirkungen auf, die meist den Gastrointestinaltrakt betrafen. In einem Fall mußte die Behandlung abgebrochen werden. Diese Ergebnisse zeigen, daß Flurithromycin Ethylsuccinat ein wirksames und sicheres Medikament für die Behandlung tiefer Atemwegsinfektionen ist.
-
Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
Infection, 1994Co-Authors: F. Bariffi, V. Clini, F. Ginesu, Patrizia Mangiarotti, Libera Romoli, Giulinana Gialdroni-grassiAbstract:Efficacy and tolerability of Flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18-87 years) were treated with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that Flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections.
F. Bariffi - One of the best experts on this subject based on the ideXlab platform.
-
Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
Infection, 1994Co-Authors: F. Bariffi, V. Clini, F. Ginesu, Patrizia Mangiarotti, Giulinana Gialdroni-grassi, Libera RomoliAbstract:Efficacy and tolerability of Flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18–87 years) were treates with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that Flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections. Die Wirksamkeit und Verträglichkeit von Flurithromycin Ethylsuccinat wurde bei Patienten mit Infektionen der tiefen Atemwege geprüft. 110 Patienten (38 Frauen, 72 Männer, im Alter von 18–87 Jahren) erhielten zweimal täglich eine Tablette Flurithromycin Ethylsuccinat zu 375 mg. Insgesamt wurden 62,9% der Patienten klinisch geheilt, 19% gebessert. Die Rate an befriedigendem klinischen Ansprechen lag somit bei 81,9%. Bei den meisten Patienten ging die Sputumproduktion zurück. Bei 47% hatte die Sputumproduktion nach Behandlungsende aufgehört (nur bei einem Patienten bestand zu Therapiebeginn keine Sputumproduktion). Purulentes oder mukopurulentes Sputum bestand vor Behandlung bei 80% und nach Behandlng bei 20% der Patienten. Bei 72 Patienten war eine bakteriologische Befundung möglich. In 80,2% der Fälle wurde der Erreger eliminiert. Bei acht der 110 behandelten Patienten traten Nebenwirkungen auf, die meist den Gastrointestinaltrakt betrafen. In einem Fall mußte die Behandlung abgebrochen werden. Diese Ergebnisse zeigen, daß Flurithromycin Ethylsuccinat ein wirksames und sicheres Medikament für die Behandlung tiefer Atemwegsinfektionen ist.
-
Flurithromycin ethylsuccinate in the treatment of lower respiratory tract bacterial infections
Infection, 1994Co-Authors: F. Bariffi, V. Clini, F. Ginesu, Patrizia Mangiarotti, Libera Romoli, Giulinana Gialdroni-grassiAbstract:Efficacy and tolerability of Flurithromycin ethylsuccinate were evaluated in lower respiratory tract infections. One hundred and ten patients (38 women, 72 men; age range 18-87 years) were treated with on 375 mg tablet 12-hourly for a mean duration of 8.7 days. One hundred and five patients were evaluable for efficacy. Overall clinical cure rate was 62.9%; improvement was recorded in 19% of patients for a total satisfactory clinical response rate of 81.9%. Sputum production decreased in most patients, being absent after treatment in 47% (only one patient was negative at baseline); sputum was purulent or mucopurulent in 80% of subjects before and in 20% after treatment. Bacteriological evaluation was possible in 72 patients: pathogen eradication was achieved in 80.2% of cases. Eight patients out of 110 reported adverse reactions, mainly gastrointestinal; in one case treatment had to be discontinued. These results demonstrate that Flurithromycin ethylsuccinate is safe and effective in the treatment of lower respiratory tract infections.
M Carbone - One of the best experts on this subject based on the ideXlab platform.
-
antimicrobial activity and postantibiotic effect of Flurithromycin against helicobacter pylori strains
International Journal of Antimicrobial Agents, 2001Co-Authors: M T Fera, G Blandino, M Giannone, S Pallio, Andrea Tortora, M CarboneAbstract:Abstract The minimal inhibitory concentrations (MIC) of Flurithromycin on 49 clinical isolates of Helicobacter pylori was investigated. The MICs were determined using an agar dilution technique. Flurithromycin inhibited the growth of H. pylori strains with MIC 50 and MIC 90 values of 0.156 and 0.625 mg/l, respectively. The postantibiotic effects (PAE) were studied on ten strains, by exposure of the bacteria to Flurithromycin at five and ten times MIC for 1 or 2 h. Regrowth was determined by measuring the viable counts after drug removal by a 10 3 dilution procedure. All PAEs increased as a function of concentration and time of exposure. The mean duration of PAEs varied between 1.5 and 6 h. These data are encouraging since macrolides play a key role in the clinical treatment of H. pylori infections, and the strong PAE caused by Flurithromycin may contribute to the in vivo efficacy of this drug.
-
Antimicrobial activity and postantibiotic effect of Flurithromycin against Helicobacter pylori strains.
International journal of antimicrobial agents, 2001Co-Authors: M T Fera, M Giannone, S Pallio, Andrea Tortora, Giovanna Blandino, M CarboneAbstract:Abstract The minimal inhibitory concentrations (MIC) of Flurithromycin on 49 clinical isolates of Helicobacter pylori was investigated. The MICs were determined using an agar dilution technique. Flurithromycin inhibited the growth of H. pylori strains with MIC 50 and MIC 90 values of 0.156 and 0.625 mg/l, respectively. The postantibiotic effects (PAE) were studied on ten strains, by exposure of the bacteria to Flurithromycin at five and ten times MIC for 1 or 2 h. Regrowth was determined by measuring the viable counts after drug removal by a 10 3 dilution procedure. All PAEs increased as a function of concentration and time of exposure. The mean duration of PAEs varied between 1.5 and 6 h. These data are encouraging since macrolides play a key role in the clinical treatment of H. pylori infections, and the strong PAE caused by Flurithromycin may contribute to the in vivo efficacy of this drug.
-
Short communication Antimicrobial activity and postantibiotic effect of Flurithromycin against Helicobacter pylori strains
2001Co-Authors: M T Fera, M Giannone, S Pallio, Andrea Tortora, Giovanna Blandino, M CarboneAbstract:The minimal inhibitory concentrations (MIC) of Flurithromycin on 49 clinical isolates of Helicobacter pylori was investigated. The MICs were determined using an agar dilution technique. Flurithromycin inhibited the growth of H. pylori strains with MIC50 and MIC90 values of 0.156 and 0.625 mg:l, respectively. The postantibiotic effects (PAE) were studied on ten strains, by exposure of the bacteria to Flurithromycin at five and ten times MIC for 1 or 2 h. Regrowth was determined by measuring the viable counts after drug removal by a 10 3 dilution procedure. All PAEs increased as a function of concentration and time of exposure. The mean duration of PAEs varied between 1.5 and 6 h. These data are encouraging since macrolides play a key role in the clinical treatment of H. pylori infections, and the strong PAE caused by Flurithromycin may contribute to the in vivo efficacy of this drug. © 2001 Published by Elsevier Science B.V. and International Society of Chemotherapy. All rights reserved.
Giuseppe Nicoletti - One of the best experts on this subject based on the ideXlab platform.
-
Antibacterial activity and post-antibiotic effect of Flurithromycin compared with other macrolides and penicillins against periodontal pathogens.
Journal of chemotherapy (Florence Italy), 2001Co-Authors: A.m. Lo Bue, I Milazzo, Giovanna Blandino, G. Pasquantonio, A. Speciale, Giuseppe NicolettiAbstract:In this study the authors examined the activity of Flurithromycin compared to that of erythromycin, spiramycin and penicillin against 107 strains of various species supposed to cause periodontitis. The range of MICs of Flurithromycin was: ≤0.06-2 mg/l for P. gingivalis (28 isolates), 0.06-2 mg/l for P. melaninogenica (7), 0.5-4 mg/l for P. intermedia (5), 0.25-8 mg/l for Prevotella sp. (8), 1-16 mg/l for F. nucleatum (14), 0.12-0.5 mg/l for W. recta (2), 0.5-32 mg/l for E. corrodens, 0.5-2 mg/l for B. forsythus (2); ≤0.06-64 mg/l for Peptostreptococcus sp. (11), ≤0.06-1 mg/l for A. odontolyticus (11) and for A. naeslundii (7) and ≤0.06-16 mg/l for A. viscosus (7). Macrolide activity was ranked in decreasing order from Flurithromycin to erythromycin to spiramycin. Beta-lactamase production was demonstrated in Prevotella sp. (20%) and in F. nucleatum (7%). Isolates which were β-lactamase negative but resistant to penicillin were found among Peptostreptococcus sp. and Actinomyces sp. A post-antibiotic effect of 2 hours was seen for Flurithromycin on P. gingivalis and E. corrodens. The good in vitro activity of Flurithromycin against bacteria supposed to cause periodontitis suggests clinical potential in the treatment of these diseases.
-
Levels of Flurithromycin in female genital tissue.
Antimicrobial agents and chemotherapy, 1995Co-Authors: Pio Maria Furneri, Antonio Cianci, L. Campo, Roccasalva L, Gianna Tempera, G Fiore, Giuseppe A. Palumbo, A. M. Lepore, Giuseppe NicolettiAbstract:The levels of Flurithromycin in gynecological tissue in 20 female patients were studied after preoperative administration. The tissue Flurithromycin levels obtained were comparable to those obtained in serum at 3 and 4 h but were frequently higher than those in serum at 6 and 12 h. Flurithromycin reached the highest concentrations in ovary at 4 h and in endometrium at 6 h.
-
In-vitro antimycoplasmal activity of Flurithromycin
The Journal of antimicrobial chemotherapy, 1995Co-Authors: Pio Maria Furneri, Gianna Tempera, G. Bisignano, G. Cerniglia, Giuseppe NicolettiAbstract:The in vitro activity of Flurithromycin, a 14-membered macrolide drug, was found to be similar to that of erythromycin against 41 strains of Mycoplasma spp. and 100 strains of Ureaplasma urealyticum. All 28 strains of Mycoplasma hominis were uniformly resistant to both macrolides with MICs > 256 mg/L, U. urealyticum showed intermediate resistance with MIC50s of 0.5 and 1 mg/L for erythromycin and Flurithromycin, respectively, whereas the ten strains of Mycoplasma pneumonia were susceptible to < or = 0.03 mg/L of both macrolides.
-
In vitro activity of Flurithromycin against some genital pathogens.
Drugs under experimental and clinical research, 1991Co-Authors: Pio Maria Furneri, Gianna Tempera, A. M. Lepore, C. Bonfanti, Giuseppe NicolettiAbstract:The in vitro antibacterial activity of a new macrolide drug, Flurithromycin, was evaluated in comparison with the activity of erythromycin A against some genital pathogens. The strains tested, C. trachomatis, U. urealyticum. M. hominis, N. gonorrhoeae, S. agalactiae and M. genitalium, were both clinically isolates and ATCC standards. The evidenced activity of Flurithromycin is similar to that of erythromycin A. Resistances with both macrolides were found in all M. hominis strains and in one strain of U. urealyticum. No particular differences are exhibited between clinical and standard microorganisms.